Skip to main content
. 2021 Jun 3;80(11):1410–1418. doi: 10.1136/annrheumdis-2021-220097

Figure 3.

Figure 3

Forest-plot of country-specific ORs and overall OR for clinical remission at 12 months in TNFi and csDMARD co-medication compared with TNFi monotherapy. Adjusted for baseline age, sex, calendar year, DAS28 and disease duration. Data from Romania are not presented separately due to <5 patients with monotherapy. csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; DAS28, Disease Activity Score with 28 joints; TNFi, tumour necrosis factor inhibitors.